Shares of Piramal Pharma (PPLPHARMA) surged by 6.56%, reaching ₹231.94 on the NSE at 9:17 AM, following a positive outlook from analyst meetings. Antique and Jefferies both highlighted the company’s ambitious plans, with Piramal Pharma aiming to achieve $2 billion in revenue by CY30, driven by its Contract Development and Manufacturing Organization (CDMO) segment and focused growth in complex hospital and consumer health portfolios.
The company’s strategy to boost EBITDA margins from ~15% to 25%, along with reducing its net debt/EBITDA ratio from 3x to under 1x by FY24, has caught investor attention. Jefferies reiterated its “Buy” rating on Piramal Pharma, raising the target price to ₹260, projecting a 20% upside from its previous close of ₹216. Positive revisions in EBITDA estimates for FY25 and FY26 have further fueled market optimism.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
